tapebrief

COO · Q2 2026 Earnings

Bearish

Cooper Companies (The)

Reported June 4, 2026

30-second summary

30-second take: Cooper printed Q2 revenue of $1.082B (+8% reported, +5% organic) and non-GAAP EPS of $1.21, but the report's actual content is the FY26 guide cut — total revenue midpoint down $23M to $4.285–$4.321B, organic growth cut 100bps to 3.5–4.5%, CVI organic cut 100bps to 3.5–4.5%, and the specific FY26 FCF guide of $600–625M withdrawn entirely in favour of a three-year "exceeds $2.2B" objective. EPS was held at $4.58–$4.66, meaning the margin/cost lever is now doing all the work to defend the EPS algorithm against a deteriorating top line — for the third consecutive Cooper guide cut on the underlying growth rate.

Headline numbers

EPS

Q2 FY2026

$1.21

Revenue

Q2 FY2026

$1.08B

+8.0% YoY

Gross margin

Q2 FY2026

68.0%

Free cash flow

Q2 FY2026

$0.10B

Operating margin

Q2 FY2026

-3.0%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$1.08B$1.00B+7.9%$1.02B+5.6%
EPS$1.21$0.96+26.0%$1.10+10.0%
Gross margin68.0%68.0%+0bps68.0%+0bps
Operating margin-3.0%18.0%-2100bps21.0%-2400bps
Free cash flow$0.10B$0.02B+432.6%$0.16B-39.3%

Guidance

Company narrowed full-year revenue and organic growth guidance downward by 100 bps, while maintaining EPS guidance and withdrawing specific FY2026 FCF forecast in favor of long-term objective.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY 2026
$4.306 - $4.346 billion$4.285 - $4.321 billion-$0.021 to -$0.025 billion (midpoint -$0.023B)Lowered
Organic Revenue Growth
FY 2026
4.5% to 5.5%3.5% to 4.5%-1.0 percentage points at both low and high endLowered
CooperVision Revenue
FY 2026
$2.906 - $2.932 billion$2.883 - $2.908 billion-$0.023 to -$0.024 billionLowered
CooperVision Organic Growth
FY 2026
4.5% to 5.5%3.5% to 4.5%-1.0 percentage points at both low and high endLowered
Free Cash Flow
FY 2026
$600 - $625 millionWithdrawn — no replacementWithdrawn

Reaffirmed unchanged this quarter: CooperSurgical Revenue ($1.402 - $1.414 billion), CooperSurgical Organic Growth (4% to 5%), Non-GAAP Diluted EPS ($4.58 - $4.66), Free Cash Flow Objective (exceeding $2.2 billion (2026-2028))

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
CooperVision$0.724B$0.67B+8.0%
CooperSurgical$0.358B$0.333B+7.6%
Toric and Multifocal$0.365B+7.0%
Sphere, Other$0.359B+1.0%
Office and Surgical$0.214B+4.0%
Fertility$0.144B+10.0%
CooperVision Organic Growth4%7%
CooperSurgical Organic Growth6%7%
Fertility Revenue Growth10% organic

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Americas$0.303B+7.0%
EMEA$0.29B+6.0%
Asia Pacific$0.131B-6.0%
Non-GAAP Operating Margin27%25%
Free Cash Flow$96.4 million
Organic Revenue Growth5%7%

Management tone

Q3 FY25 demand-conversion uncertainty → Q4 FY25 strategic review and reorganisation → Q1 FY26 margin-and-cash victory lap → Q2 FY26 guide cut with EPS defence.

Transcript prepared remarks were not available for this brief — tone analysis below is constructed from press-release language compared against prior-quarter prepared remarks and Q&A.

Management's framing of the operating environment has shifted from confident to defensive across four quarters. Q4 FY25's press release led with strategic-review optionality and a raised three-year FCF target. Q1 FY26 led with "outstanding profitability and robust cash flow." This quarter's press release language pivots to "maintaining discipline in a dynamic operating environment" — language that did not appear in the prior two releases. The phrase "dynamic operating environment" is the kind of qualifier companies introduce when they need cover for a guide cut they're embarrassed about. The release simultaneously cuts the FY organic growth rate and withdraws specific FCF guidance — that is the substantive content behind the new tone.

The "back-half loaded" thesis from Q4 FY25 has quietly been abandoned without acknowledgement. Q4 FY25 management committed publicly that CVI FY26 organic growth would land in +4.5–5.5%, with strongest performance in Q3 and Q4. After Q1's +3% miss management reaffirmed the FY range. This quarter, with CVI organic at +4% — still below the prior FY midpoint with only two quarters left — management cut the FY range rather than continue defending the ramp. The implicit admission is that the H2 acceleration is no longer there to defend. Given the cut took the FY range to +3.5–4.5% and Q2 printed +4%, the remaining quarters need to average roughly the +4% level Cooper just achieved — the bar is now "do not decelerate from here" rather than "accelerate from here."

The FCF guide withdrawal continues a recurring Cooper pattern of pulling specific cash guidance under pressure and substituting longer-dated framework language. Q3 FY25 saw the FY25 FCF guide withdrawn. Q4 FY25 reset with an explicit FY26 $575–625M range. Q1 FY26 raised it to $600–625M. Q2 FY26 withdraws it again. In each case the multi-year framework objective ($2.2B+ over 2026–2028) is reaffirmed in place of the specific annual number — but the framework target has never been broken into a year-by-year bridge. When the specific guide is the one that keeps disappearing, the framework target is doing a job it wasn't designed for.

Strategic-review silence has now persisted for two consecutive quarters. Q4 FY25 announced a formal board-led review with explicit language about "exploring every opportunity to unlock long-term shareholder value." Q1 FY26 made no substantive update. Q2 FY26's release adds nothing beyond standard operating commentary. Formal strategic reviews announced in December typically deliver advisor identification within one quarter and a scope decision within two. Cooper has now reported two quarters of operating updates with zero process disclosure on the most material structural decision in front of the company.

Fertility is the one segment where the prior framing has been validated by the print. Q4 FY25 management committed publicly that fertility would inflect to mid-single digits and "a little faster" by year-end. Q1 printed +6%. Q2 prints +10%. This is the only line in the release where the multi-quarter thesis has converted from forward-looking language to observed reality. CSI organic of +6% (above the +4–5% FY guide) is being driven primarily by this fertility acceleration.

Answers to last quarter's watch list

Q2 FY26 CVI organic landing above +4.5%. CVI organic landed at +4% — below the +4.5% threshold and below the FY +4.5–5.5% range that was in place coming into the quarter. The threshold was missed and the response was a 100bps FY guide cut, exactly the "crack the FY EPS bridge" scenario flagged last quarter — except EPS was held intact by the cost lever rather than allowed to break.
Resolved negatively
Asia-Pacific returning to flat-or-better organic. Asia-Pacific reported -6% in Q2, worse than Q1's -4% and Q4 FY25's flat print. The lapped-drag thesis ("we're not going to see the same detriment in 26 that we saw in 25") has now failed for three consecutive quarters of deteriorating prints.
Resolved negatively
Strategic review disclosure. The press release contains no advisor identification, no scope confirmation, and no board update for the second consecutive quarter. By the timeline benchmark set last quarter (advisor names + scope by Q2 reporting), the process has visibly stalled.
Resolved negatively
Paragard competitive launch timing. Office & Surgical printed +4% reported, materially better than the H2 FY25 air pocket — consistent with the competitive launch having slipped. The press release does not explicitly quantify it. The implied upside source flagged last quarter appears to have partially materialised but management is not banking it in the guide.
Continue monitoring
Buyback pace. The release discloses $13.1M of Q2 repurchases (~174k shares at $75.84 average), with $860.8M remaining on the authorisation. That is a notably light pace relative to the two-thirds-of-FCF framework — Q2 FCF was $96.4M, so buybacks ran at ~14% of FCF this quarter. With the specific FY FCF guide withdrawn, the framework is now operating against an undisclosed cash denominator. Status: Partially resolved — pace is light

What to watch into next quarter

Q3 FY26 CVI organic above +4%. With the FY guide now at +3.5–4.5% and Q2 at +4%, Q3 needs to hold the +4% level or the FY guide gets cut a fourth time. A Q3 print below +3.5% would force a guide cut on consecutive quarters and break the EPS algorithm's last cost-savings buffer.

FCF disclosure cadence — does Cooper restore a specific FY guide. Withdrawing the FY26 FCF guide while reaffirming the three-year >$2.2B objective is unsustainable as a communication posture beyond one quarter. Watch whether Q3 either restores a specific FY26 range or formally migrates to a multi-year-only framework — the latter would be a meaningful negative signal on near-term cash conversion.

Strategic review — Q3 is the put-up-or-shut-up call. Two consecutive quarters of silence after a December 2025 announcement is the upper bound of what is credibly "in process." If Q3 reports yet another quarter with no advisor names, scope, or board commentary, the market should infer the review has reached a no-action conclusion that management has not publicly acknowledged.

Asia-Pacific Q3 organic print. A fourth consecutive negative print would force management to abandon the lapped-drag framework entirely and disclose either a structural China/Japan exit, a write-down, or a strategic alternative for the region.

GAAP-to-non-GAAP bridge in the 10-Q. The $1.61/share gap between GAAP -$0.40 and non-GAAP $1.21 EPS this quarter is unusually wide and dominated by the $271.6M CSI recall litigation charge. Watch whether the final settlement scope expands beyond the accrued $324.1M gross liability and whether insurance recoveries actually convert at the assumed $52.5M level.

Sources

  1. Cooper Companies Q2 FY2026 press release, filed 2026-06-04: https://www.sec.gov/Archives/edgar/data/711404/000162828026040823/cooperq22026pressrelease.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.